Cancer Types | Breast Cancer - National Foundation for Cancer Research

Breast Cancer

Breast Cancer

Breast cancer is the most common cancer in women worldwide, claiming the lives of hundreds of thousands of women each year. Although it’s rare, men can also be diagnosed with breast cancer. With breast cancer continuing to impact so many people, it’s important to understand the disease and what strides researchers are making.

Key Facts

  • An estimated 279,100 new cases of breast cancer will be diagnosed in the U.S. in 2020, and an estimated 42,690 deaths will occur.
  • More than 3.5 million breast cancer survivors live in the U.S. today.
  • The lifetime risk of getting breast cancer in the U.S. is about 1 in 8 for women and 1 in 833 for men.
  • Research shows only 5-10% of breast cancers are hereditary.
  • Dense breasts can be 1.5 to 2 times more likely to develop cancer. If you have dense breasts, ask your doctor about extra screening tests, like ultrasound or MRI, to check for tumors that a mammography might have missed.
  • A lump isn’t the only sign of breast cancer. Call your doctor if you notice a change in the size or shape of your breast, a nipple turned inward, fluid other than breast milk, dimples in your breast or scaly, red or swollen skin on your breast, nipple or areola.
  • Triple-negative breast cancer differs from other types of invasive breast cancer as they grow and spread faster, have limited treatment options, and a worse prognosis (outcome).
Source: American Cancer Society’s Cancer Facts & Figures 2020
Pink Breast Cancer Ribbon
3500000
survivors in the U.S. today
1
in 8 women will be diagnosed
2
times more likely with dense breasts

Breast Cancer Research

In addition to specific projects listed below, genomics research is helping us attack breast cancer – and all types of cancer. NFCR has distinguished itself from other organizations by emphasizing long-term, transformative research and working to move people toward cancer genomics.

Susan B. Horwitz, Ph.D.
Susan B. Horwitz, Ph.D.

Dr. Susan Horwitz’s work has been instrumental in the development of Taxol®, a natural product drug used to treat over 1.5 million breast, ovarian, lung and pancreatic cancer patients. Dr. Horwitz is collaborating with organic chemist, Dr. Amos B. Smith III, to develop other natural products to overcome resistance to Taxol that patients may experience. The scientists are testing the effectiveness and toxicity of the leading synthetic analogues of discodermolide, a natural product from a Caribbean Sea sponge, for a new treatment for triple negative breast cancer and other cancers.

Amos B. Smith III, Ph.D.
Amos B. Smith III, Ph.D.
Daniel A. Haber, Ph.D.
Daniel A. Haber, M.D., Ph.D.

NFCR-funded scientist Dr. Daniel Haber developed the CTC-iChip — an advanced micro-engineered device that captures circulating tumor cells from the blood that may metastasize to a vital organ. His team is using the gene-editing tool, CRISPR, to identify and turn on or off the genes that regulate the ability of CTC’s to metastasize (spread) from breast tumors. Several candidate genes have been identified. Ultimately, therapies will be developed that suppress the genes and give women greater hope for surviving the metastatic recurrence of breast cancer.

James P. Basilion, Ph.D.
James P. Basilion, Ph.D.

Dr. Jim Basilion has developed a “smart” probe that when topically applied to the cancer during surgery, the ability of surgeons to detect tumor margins is greatly improved. The smart probe will fulfill the unmet clinical need to reduce repeat surgeries at a later time for removal of remaining cancer tissue which for lumpectomies, can be 25% of the time. The probe may also reduce the chance of cancer spread. With support from the NFCR AIM-HI Translational Research Initiative, the probe is being optimized for next-steps towards a Phase I clinical trial for lumpectomies to further enhance cure rates for patients with early stage breast cancer.

Xiang-Lei Yang, Ph.D. and Paul Schimmel, Ph.D.
Xiang-Lei Yang, Ph.D. and Paul Schimmel, Ph.D.

Aminoacyl-tRNA synthetases (aaRS) are vital ancient enzymes that make proteins in all living things. Dr. Paul Schimmel and Dr. Xiang-Lei Yang, experts in aaRS research, also study the enzyme’s other unexpected roles. One aaRS, SerRS, inhibits a pro-cancer gene and thwarts cancer’s growth and may play a role in activating the immune system to inhibit tumor progression. Expression of SerRS positively correlates with greater survival in patients with triple negative breast cancer and those with ovarian, colorectal, stomach, and thyroid cancers as well as gliomas. SerRS may also be a suppressor of metastasis as enzyme levels are significantly decreased in breast tissue during metastasis. This critical research may lead to a novel way to treat triple negative breast cancer and other cancer types, offering patients hope for a new therapy.

Danny R. Welch, Ph.D.
Danny R. Welch, Ph.D.

Dr. Danny Welch and his team are exploring how mitochondria – a specialized cell part that generates energy for our bodies – may determine why breast cancer metastases develop in some patients, but not in others. Differences in tumor formation, metastasis location and responses to therapy could be from our mitochondrial DNA. With continued success, this research may suggest that a simple blood test can guide doctors in treating those patients who are susceptible to metastasis and may need more aggressive treatment. Or, such a blood test could spare patients at low risk from having to undergo some of the side effects of treatment.

Dr. Welch’s team has also discovered eight genes that get turned off when cancer cells become metastatic cells. BRMS1 gene was discovered in breast cancer cells and it regulates gene expression to suppress metastasis. BRMS1 also makes metastatic cells remain dormant or in a ‘sleep mode’. Research by the Welch team can lead to unique anti-metastasis therapeutics for breast cancer such as smaller proteins that ‘mimic’ the function of BRMS1 protein and could arrest metastasis. 

Dr. Ron DePinho
Ronald A. DePinho, M.D.

One of the major signaling proteins in tumor formation and suppression of our immune system in over 50% of cancers is STAT3. As an activator of the expression of genes, STAT3 controls networks of genes that allow cancer growth and metastasis (spreading). However, the development of a drug that targets STAT3 has been a challenge for the research community, earning STAT3 the label of ‘undruggable’.

Dr. Ron DePinho and his colleagues used computer-based drug screening of hundreds of thousands of compounds from chemical libraries to identify several compounds that inhibit STAT3 protein in complex tumor models of various cancer types. With funds from the NFCR AIM-HI Translational Research Initiative, the scientists have brought the lead inhibitor agent to clinical trials. Patients with triple negative breast cancer and other advanced cancers are being treated today with the STAT3 inhibitor, giving them hope that their lives may be saved.

Related Content

The Forgotten Men of Breast Cancer

Breast Cancer Awareness Month, observed during October, presents many opportunities to acknowledge patients and survivors as well as opportunities to remind women to schedule their regular screening. The world lights up in pink, the color of the breast cancer ribbon, and shares messages of support to those affected. With 1 in 8 women estimated to be diagnosed with breast cancer at some point in her life, October reminds us all how important it is to self-examine one’s breasts as well as to schedule a mammogram. However, in the urgent messaging towards women, the men affected by breast cancer are often forgotten.  About Male Breast Cancer Breast cancer in men is rare, but it does affect approximately 2,000 men in the United States each year. Though this only accounts for about 1% of all breast cancer diagnoses in the United States, it is important that men are aware of their risk of developing breast cancer. Many men, and women for that matter, are not aware that breast cancer affects both sexes. However, the truth is that all people are born with breast tissue making every individual susceptible to the disease. Of the men who develop breast cancer, the majority of the cases are infiltrating ductal carcinoma (IDC). IDC means that the cells in or around the ducts begin to invade the surrounding tissue. Breast Cancer Detection for Men Acknowledging that men can be diagnosed with breast cancer is the first step in protecting oneself from the disease. This knowledge allows men to pay attention to changes in the breast or nipple area and to speak to a doctor when identifying such changes. A common warning sign of breast cancer is a lump in the breast, chest, or underarm region. These lumps are often painless but should trigger men’s concern. Other early warning signs include dimpling or puckering of the skin, change in the size of the breast region, changes to the skin texture, an inverted nipple, or even discharge from the nipple. When men identify these warning signs and speak to a doctor, the likelihood of treating cancer at an early stage increases significantly. Treating cancer at an early stage gives all patients a higher chance of survival.  While all men should be monitoring their bodies for unusual changes, some specific men are at an increased risk of breast cancer. In general, men over 60 years old and those with a family history of cancer are at an increased risk for cancer. Overweight and obese men are also at an increased risk. Additionally, researchers have discovered that men with a specific gene mutation are more likely to develop breast cancer than those without it. The BRCA2 gene mutation is an inherited mutation and not only increases the likelihood of breast cancer but other cancers as well.  Throughout Breast Cancer Awareness Month, the public is made aware of the recommended screening processes for women concerning breast cancer. However, since breast cancer is quite rare amongst men, there are no recommended screenings for the average man. This makes it especially important for men to monitor their bodies for changes and speak to a doctor if they have any concerns. Those who have a […]

Mastectomy and Breast Reconstruction: What Breast Cancer Patients Should Know

Mastectomy is just one of the treatment options available to breast cancer patients. Learn more about what to expect before, during, and after the procedure, as well as some tips to help you prepare. A breast cancer diagnosis can be devastating, and navigating potential treatment options can be stressful and overwhelming. One treatment option available to some breast cancer patients is undergoing a mastectomy—the surgical removal of the entire breast.  Understanding Your Options Mastectomy is typically recommended for breast cancer patients who1: do not want or are unable to have radiation therapy have previously undergone surgery to remove cancer in the breast  have multiple tumors in the same breast have a large tumor (greater than five centimeters) have a genetic factor (such as BRCA) that increases the chance for cancer recurrence in the future  or have been diagnosed with inflammatory breast cancer However, as with many other cancer treatments, there is no “one size fits all” approach when it comes to mastectomy. In fact, there are five different types of mastectomies2, including: ●       Partial Mastectomy: The surgeon removes the breast tissue in which cancer cells have been detected, as well as a predetermined margin of normal tissue from the surrounding area. ●       “Simple” or “Total” Mastectomy: The surgeon removes the whole breast but does not touch the lymph nodes in the underarm area or the muscles below the breast. ●       Modified Radical Mastectomy: The surgeon removes the whole breast as well as the lymph nodes in the underarm area. The muscles below the breast remain untouched. ●       Radical Mastectomy: The surgeon removes the whole breast, all surrounding lymph nodes, and the muscles below the breast. ●       Nipple-sparing Mastectomy: The surgeon removes the whole breast, but the nipple is left intact. Undergoing Mastectomy: What to Expect Mastectomy is a major surgical procedure. Patients may alleviate some of the stress associated with surgery by educating themselves about what to expect before, during, and after the procedure. Before your procedure, it helps to make a list of questions and bring them with you when you visit your surgeon. Getting answers to questions such as: “What are the risks associated with this treatment?” “How can I best prepare myself emotionally for the surgery?” and “What will the surgery and my hospital stay be like?” can help you gain valuable insight about the procedure.3 After your mastectomy, expect to remain in the hospital for one or two nights before being discharged. At discharge, your health care team will provide you and your caregiver with written instructions about how to best care for the surgery site and dressing, how to spot signs of infection, and how to bathe properly.1 You might experience some side effects as a result of a mastectomy, including pain and swelling around the surgery site, a build-up of blood or fluid at the surgery site, and numbness in the chest or arm.1 Full recovery will depend on several factors, including the type of mastectomy your surgeon performed and whether or not you also had breast reconstruction done. Many patients can return to normal […]

From Certified Nursing Assistant to Patient: Life on the Other Side of the Bed

Hearing the word ‘cancer’ often sends chills down the spine and sends goosebumps up the neck. It is one of the most intimidating diseases, especially as it can affect nearly any part of the body. Though for some, cancer is a normal part of daily life. Jenny Dziuba, who works as a certified nursing assistant, has seen many patients battle cancer diagnoses. Early in 2019, however, Jenny experienced cancer in a new way. “My father died from lung and liver cancer two years ago,” Jenny began. “My mother had breast cancer and lymph node cancer and is still in remission, so cancer isn’t anything new to me. I’ve always been the care provider, though, so you can imagine how hard it was to be on the other side of the bed.” One morning, Jenny began to notice a painful lump in her breast tissue and a leaking milk duct. It was a feeling she knew well, having frequent fibrous cysts in her breasts. This particular cyst had been regularly monitored with mammograms over the past two years, but the pain was becoming increasingly aggravating. During her next routine appointment, the care team wasn’t satisfied with just a mammogram. They first recommended an ultrasound, but the density of the breast tissue was more suitable for a biopsy. “The biopsy was kind of painful afterwards,” Jenny reflected. “It felt like a bee sting that wouldn’t stop stinging, but ice helped tremendously. The day after was much better but the results came back positive, so they needed to do two more biopsies.” Though it was a day that would typically warrant a cause for celebration, Jenny spent her twentieth wedding anniversary undergoing both biopsies. As if the results were an anniversary gift themselves, Jenny was informed that both biopsies came back negative. She and the care team were excited, but there was still another lump that would require monitoring. In the meantime, Jenny was referred to her primary care physician to discuss a treatment plan. “My physician recommended a mastectomy because of my family history,” Jenny explained. “I was ok with that, but I was then told that it wouldn’t be possible to remove all breast tissue and I could still get cancer in the remaining tissue. The only problem being that I wouldn’t be able to get a mammogram to find it. A lumpectomy would have a much higher chance of cancer coming back, but it could easily be found by a mammogram.” Luckily, Jenny’s surgeon put her internal debating to rest. He informed her that her cancer was still confined to one area, so it would be better to remove the lump rather than perform an aggressive mastectomy. Her surgery was scheduled almost exactly six months from her original diagnosis, with radiation therapy planned several weeks afterwards. The treatment would be done five times a week for four weeks. “The biggest challenge was trying to work with all these appointments and treatments, especially while having a son still in school,” Jenny reflected. “I was never scared, but I wished they had explained the procedures better. I didn’t know it would be […]